# Visual I Study 👉🏼WHAT IS IT ? Adalimumab for noninfectious intermediate, posterior, or panuveitis 👉🏼 CONCLUSION * the ADA group was less likely than the placebo group to have treatment failure adverse events * serious adverse events were more common in the ADA group